Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Hospitalization for heart failure marks a fundamental change in the natural history of the disease and portends a poor prognosis for the patients. For those without a history of heart failure, a hospitalization signals development of new onset heart failure that is associated with 40–50% 5-year mortality risk.1 Amongst those with a previous history of heart failure, worsening symptoms leading to hospitalization are associated with ∼20–25% 1 year mortality risk, a ∼20% 4-week readmission risk and a ∼50% 6-month readmission risk.1 In observational studies, these risks are apparent whether a person has heart failure with reduced or preserved ejection fraction.2 Recent clinical trials have demonstrated that worsening heart failure is associated with the highest absolute risk of heart failure hospitalization, followed by chronic heart failure with reduced ejection fraction, and then chronic heart failure with preserved ejection fraction in the outpatient setting. Relative to patients with manifest heart failure, the absolute risk of heart failure hospitalizations is lower in populations with chronic kidney disease and diabetes without prevalent heart failure, but these patients nevertheless are at a higher risk than those without these comorbidities. Indeed, in patients with diabetes mellitus, the risk for heart failure has been shown to be higher and less amenable to reduction with risk factor control than myocardial infarction and diabetes.3 Besides portending risk, these hospitalizations are associated with high costs, both to an individual as well as the society, accounting for most of the overall annual direct cost of care related to heart failure.1 Thus, prevention of hospitalizations for heart failure is an important clinical, patient-centric and societal goal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ertugliflozin did not reduce the combined endpoint of CV death or HF hospitalization, although there was a significant reduction in HF hospitalization and repeated hospitalizations.154,541”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [541]
In the citing paper
“Diabetes and AF frequently co-exist, and when this occurs, there is a substantially higher risk of all-cause death, CV death, stroke, kidney disease, and HF, regardless of diabetes type.541,577,[591][592][593][594][595][596]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [541]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationTrends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationEmpagliflozin after Acute Myocardial Infarction
Butler, J., Jones, W. S., Udell, J. A., Anker, S. D., Petrie, M. C., Harrington, J., Mattheus, M., Zwiener, I., Amir, O., Bahit, M. C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2314051 · Cited by 301
Self-citationEffect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Usman, M., Siddiqi, T. J., Anker, S. D., Bakris, G. L., Bhatt, D. L., Filippatos, G. S., Fonarow, G. C., Greene, S. J., Januzzi, J. L., Khan, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.034 · Cited by 187
Self-citationUsman, M., Bhatt, D. L., Hameed, I., Anker, S. D., CHENG, A. Y. Y., Hernandez, A. F., Jones, W. S., Khan, M. S., Petrie, M. C., Udell, J. A., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00102-5 · Cited by 166
Self-citation2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Metadata
- Authors
- Butler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M.
- Affiliations
- University of Mississippi Medical Center (US)
- Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
- National and Kapodistrian University of Athens (GR)
- Université de Lorraine, Inserm INI-CRCT, CHRU , 34 Cr Léopold, Nancy 54000, France
- Inserm (FR)
- Baylor Heart and Vascular Institute , 621 North Hall Street, Dallas, TX, USA
- Corresponding author
- Butler, Javed
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-10-30
- Volume
- 42
- Issue
- 48
- Pages
- 4887-4890
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W3210386024
- Cited by
- 18
- References
- 17
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 1
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- heart failure hospitalization, heart failure outcomes, heart failure with reduced ejection fraction, chronic kidney disease, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucose, Heart Failure, Humans, Sodium, Symporters
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. https://app.cochat.ai/papers/10.1093/eurheartj/ehab704
- The paper
- Butler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M. (2021). Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab704
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.